Pulse Biosciences IncNASDAQ:PLSE
- LAST PRICE7.9600
- TODAY'S CHANGE (%)0.3600 (4.7368%)
- Bid / Lots7.9800/ 2
- Ask / Lots8.0400/ 4
- Open / Previous Close7.7100 / 7.6000
- Day Range
- 52 Week Range
- Volume63,676
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PLSE |
|---|---|---|
| 09:32 ET | 1983 | 7.52 |
| 09:34 ET | 500 | 7.6 |
| 09:52 ET | 100 | 7.55 |
| 09:56 ET | 2088 | 7.525 |
| 09:57 ET | 700 | 7.59 |
| 09:59 ET | 455 | 7.61 |
| 10:01 ET | 200 | 7.61 |
| 10:03 ET | 100 | 7.71 |
| 10:08 ET | 671 | 7.71 |
| 10:10 ET | 100 | 7.66 |
| 10:15 ET | 100 | 7.69 |
| 10:19 ET | 100 | 7.71 |
| 10:21 ET | 100 | 7.68 |
| 10:30 ET | 100 | 7.75 |
| 10:32 ET | 100 | 7.71 |
| 10:33 ET | 6323 | 7.74 |
| 10:35 ET | 200 | 7.74 |
| 10:44 ET | 200 | 7.745 |
| 10:46 ET | 400 | 7.85 |
| 10:48 ET | 100 | 7.81 |
| 10:50 ET | 100 | 7.9099 |
| 10:51 ET | 100 | 7.87 |
| 10:53 ET | 400 | 7.87 |
| 10:55 ET | 700 | 7.8988 |
| 10:57 ET | 7800 | 7.94 |
| 11:00 ET | 3199 | 8.06 |
| 11:02 ET | 1661 | 7.96 |
| 11:04 ET | 2544 | 7.855 |
| 11:06 ET | 1798 | 7.81 |
| 11:08 ET | 100 | 7.81 |
| 11:11 ET | 100 | 7.81 |
| 11:13 ET | 928 | 7.98 |
| 11:15 ET | 100 | 7.915 |
| 11:22 ET | 2200 | 7.865 |
| 11:26 ET | 100 | 7.87 |
| 11:29 ET | 100 | 7.87 |
| 11:33 ET | 820 | 7.945 |
| 11:36 ET | 100 | 7.89 |
| 11:40 ET | 378 | 8.02 |
| 11:45 ET | 400 | 8.0118 |
| 11:47 ET | 700 | 8.01 |
| 11:49 ET | 2835 | 7.93 |
| 11:51 ET | 200 | 7.93 |
| 11:54 ET | 100 | 7.91 |
| 11:58 ET | 100 | 7.89 |
| 12:00 ET | 100 | 7.9 |
| 12:02 ET | 100 | 7.9 |
| 12:18 ET | 400 | 7.95 |
| 12:20 ET | 400 | 7.95 |
| 12:21 ET | 2543 | 7.9799 |
| 12:23 ET | 300 | 7.89 |
| 12:25 ET | 7180 | 8 |
| 12:30 ET | 226 | 7.94 |
| 12:36 ET | 207 | 7.96 |
| 12:38 ET | 100 | 7.96 |
| 12:50 ET | 100 | 7.96 |
Today
Apr 24, 2024
Press Release: Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024, from 4:49PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:49PM ET on Wednesday Apr 24, 2024 by Dow JonesPulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024, from 4:05PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:05PM ET on Wednesday Apr 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pulse Biosciences Inc | 419.7M | -8.9x | --- |
Cibus Inc | 423.7M | -0.8x | --- |
Nano-X Imaging Ltd | 529.3M | -8.5x | --- |
MaxCyte Inc | 394.6M | -10.3x | --- |
Orchestra Biomed Holdings Inc | 157.4M | -3.0x | --- |
Envoy Medical Inc | 86.8M | -1.8x | --- |
Company Information
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Contact Information
- Headquarters
- 3957 Point Eden WayHAYWARD, CA, United States 94545-3720
- Phone
- 510-906-4600
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Robert Duggan
- Chief Commercial Officer
- Kevin Danahy
- Chief Technology Officer, Director
- Darrin Uecker
- Chief Science Officer - Cardiac Surgery
- Niv Ad
- Chief Medical Officer
- Gansevoort Dunnington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $419.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.65 |
EPS | $-0.89 |
Book Value | $0.80 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
